Open access
Open access
Powered by Google Translator Translator

FDA Safety Communication: Biotin Supplements May Result in Falsely Low Troponin Results

10 Nov, 2019 | 13:43h | UTC

UPDATE: The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication – U.S Food and Drug Administration (free)

Commentary: FDA Updates Warning on Biotin Interfering with Lab Results – NEJM Journal Watch (free)

“…the FDA is particularly concerned about biotin interference causing a falsely low result for troponin, a clinically important biomarker to aid in the diagnosis of heart attacks, which may lead to a missed diagnosis and potentially serious clinical implications. The FDA continues to receive adverse events reports indicating biotin interference caused falsely low troponin results.”

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.